Tuesday, July 1, 2025 7/1/2025

Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL

Award Number: R01CA282408
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL - ABSTRACT Adoptive T cell therapy (ACT) is a promising approach for treating patients with advanced malignancies. Advances in molecular biology and genetic engineering have led to the design and use of modified T cells that can recognize tumors to achieve significant tumor control upon ACT to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Yet, elimination of established tumors has not been effectively achieved, typically due to loss of T-cell effector function or failure of long-term survival. Most ACT trials use rapidly expanded T cells that are terminally differentiated and exhibit an effector memory (Tem) phenotype. These Tem phenotypes bearing cells are more susceptible to the adverse effects of the tumor microenvironment (TME). Therefore, the development of novel mechanism based therapeutic strategies that can reprogram anti-tumor T cells to maintain their metabolic fitness and effector function in a tumor microenvironment is urgently needed to enhance the therapeutic value of ACT. Our Phase I clinical trial in this proposal builds on strong in vivo pre-clinical tumor control data obtained using novel ex vivo programming conditions that merge robust phenotypes of both Th1 and Th17 cells to generate a hybrid Th1/17 cell. We have recently established that programming conditions that bring together ‘anti-tumor effector function’ of Th1 cells and ‘stemness’ of Th17 cells lead to a superior hybrid Th1/17 (and Tc/17) cell exhibiting long-term tumor control. CD19 CAR T-cell therapy (CD19-CTCT) represents an enormous scientific and clinical breakthrough for patients with CD19-positive non-Hodgkin lymphoma (NHL), however, major issues still remain regarding toxicity and with the majority of patients succumbing to disease relapse. Thus, we hypothesize that ex vivo expansion and programming of CD19-CAR-Ts to metabolically enhanced hybrid T1/17 (Th1/17 and Tc1/17) phenotype will lead to robust anti-tumor control even with fewer adoptively transferred cells. Additionally, we have used cytoplasmically truncated CD34 tag (CD34t) into the CAR T cell construct to enable a more purified CAR T-cell product via CD34 selection, which aims to improve CAR T-cell antigen reactivity, persistence, and reduces off-target toxicities. Following specific aims are proposed to establish and develop our approach for commercialization: Specific Aim 1: Define a safe dose of meCD19- CD34t-CAR-T cells while evaluating efficacy for R/R B-cell NHL and CLL/SLL. Specific Aim 2: Establish pre- and post-infusion molecular signature and its correlation to anti-tumor response. We believe that this proposal will help adopt the novel ex vivo programming conditions for generating robust anti-tumor CAR-Ts that could be used in future in clinical trials to target other malignancies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $532,785 )
2025	2025	THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Treatment Research	001	2	5/23/2025	NON-COMPETING CONTINUATION	$53,279
2025	2025	THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Treatment Research	000	2	3/6/2025	NON-COMPETING CONTINUATION	$479,506
														Subtotal = $532,785

Issue Date FY: 2024 ( Subtotal = $533,348 )
2024	2024	THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Treatment Research	000	1	3/22/2024	NEW	$533,348
														Subtotal = $533,348

Grand Total All Awards = $1,066,133

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL

Award Number: R01CA282408

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer